Mary Reumuth
Director of Finance/CFO bij KALA BIO, INC.
Vermogen: 582 211 $ op 31-03-2024
Profiel
Mary E.
Reumuth is currently an Independent Director at Olink Holding AB since 2022 and the Chief Financial Officer at KALA BIO, Inc. since 2014.
Previously, she worked as a Finance Director at Verenium Corp.
from 2007 to 2011 and as a Controller at Enobia Pharma, Inc. from 2011 to 2012.
She also held positions as an Auditor at Ernst & Young LLP and as a Manager-External Financial Reporting at Genzyme Corp.
Ms. Reumuth obtained her undergraduate degree from Texas A&M University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
KALA BIO, INC.
2.46% | 04-01-2024 | 66 136 ( 2.46% ) | 527 104 $ | 31-03-2024 |
OLINK HOLDING AB
0.00% | 05-02-2024 | 2 344 ( 0.00% ) | 55 107 $ | 31-03-2024 |
Actieve functies van Mary Reumuth
Bedrijven | Functie | Begin |
---|---|---|
KALA BIO, INC. | Director of Finance/CFO | 01-02-2014 |
OLINK HOLDING AB | Director/Board Member | 07-04-2022 |
Eerdere bekende functies van Mary Reumuth
Bedrijven | Functie | Einde |
---|---|---|
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Comptroller/Controller/Auditor | 01-06-2012 |
VERENIUM CORP | Director of Finance/CFO | 01-03-2011 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Opleiding van Mary Reumuth
Texas A&M University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
KALA BIO, INC. | Health Technology |
OLINK HOLDING AB | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Verenium Corp.
Verenium Corp. BiotechnologyHealth Technology Verenium Corp. produces cellulosic ethanol derived from multiple biomass feedstocks. It manufactures and markets enzyme products in the fields of animal health and nutrition, grain processing, oilseed processing, oilfield services and other industrial processes such as pulp and paper and textiles. The company was founded in December 1992 and is headquartered in San Diego, CA. | Health Technology |